Hengrui Pharmaceuticals' medicinal methini capsule has been approved for clinical trials of the drug

On January 8, Hengrui Pharmaceuticals announced that it had recently received a "Notice of Approval for Clinical Trials of Drugs" issued by the State Drug Administration regarding apple acid famini capsules and SHR-1701 injections, and that clinical trials would be conducted in the near future.
, drug basic situation 1, drug basic situation 2, drug other conditions of the company's apple acid firminini capsule is the company's innovative research and development of small molecule multi-target tyrosine kinase inhibitors.
inquiries, apple acid famini at home and abroad at home and abroad have Sorafini, Shoni tinini, Peezopani and other similar products have been approved for listing.
Solafoni was developed by Bayer and approved for listing in the United States in 2005;
three multi-target inhibitors have been approved for listing in China.
, Solapini, Schonitini, and Peropani have global sales of approximately $2,159 million in 2019.
, the product has invested a cumulative total of about 128.34 million yuan in research and development.
SHR-1701 can promote the active effect of T cells, but also can effectively improve the tumor micro-environment immune regulation, and ultimately effectively promote the immune system to kill tumor cells.
inquiries, Merck KGaA's similar products at home and abroad are in the clinical trial stage, adaptive to advanced malignancies mainly.
domestic and foreign products have not been approved for listing, there is no relevant sales data.
, the product has invested a cumulative total of about 122.46 million yuan in research and development.
in accordance with the relevant laws and regulations of China's drug registration requirements, drugs after obtaining the drug clinical trial approval notice, still need to carry out clinical trials and by the State Drug Administration review, approval and approval before production and listing.
。